These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 2353943)

  • 1. In vivo activity of human recombinant tissue inhibitor of metalloproteinases (TIMP). Activity against human stromelysin in vitro and in the rat pleural cavity.
    Lark MW; Saphos CA; Walakovits LA; Moore VL
    Biochem Pharmacol; 1990 Jun; 39(12):2041-9. PubMed ID: 2353943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contribution of the C-terminal domain of metalloproteinases to binding by tissue inhibitor of metalloproteinases. C-terminal truncated stromelysin and matrilysin exhibit equally compromised binding affinities as compared to full-length stromelysin.
    Baragi VM; Fliszar CJ; Conroy MC; Ye QZ; Shipley JM; Welgus HG
    J Biol Chem; 1994 Apr; 269(17):12692-7. PubMed ID: 8175679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stromelysin, tissue inhibitor of metalloproteinases and proteoglycan fragments in human knee joint fluid after injury.
    Lohmander LS; Hoerrner LA; Dahlberg L; Roos H; Björnsson S; Lark MW
    J Rheumatol; 1993 Aug; 20(8):1362-8. PubMed ID: 8230020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dissociation of tissue inhibitor of metalloproteinases (TIMP) from enzyme complexes yields fully active inhibitor.
    Murphy G; Koklitis P; Carne AF
    Biochem J; 1989 Aug; 261(3):1031-4. PubMed ID: 2803233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different domain interactions are involved in the binding of tissue inhibitors of metalloproteinases to stromelysin-1 and gelatinase A.
    Nguyen Q; Willenbrock F; Cockett MI; O'Shea M; Docherty AJ; Murphy G
    Biochemistry; 1994 Mar; 33(8):2089-95. PubMed ID: 8117665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metalloproteinases, tissue inhibitor, and proteoglycan fragments in knee synovial fluid in human osteoarthritis.
    Lohmander LS; Hoerrner LA; Lark MW
    Arthritis Rheum; 1993 Feb; 36(2):181-9. PubMed ID: 8431206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of metalloproteinases in human osteoarthritis.
    Woessner JF; Gunja-Smith Z
    J Rheumatol Suppl; 1991 Feb; 27():99-101. PubMed ID: 1851233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in human gliomas.
    Nakano A; Tani E; Miyazaki K; Yamamoto Y; Furuyama J
    J Neurosurg; 1995 Aug; 83(2):298-307. PubMed ID: 7616276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunoassays for the detection of human collagenase, stromelysin, tissue inhibitor of metalloproteinases (TIMP) and enzyme-inhibitor complexes.
    Cooksley S; Hipkiss JB; Tickle SP; Holmes-Ievers E; Docherty AJ; Murphy G; Lawson AD
    Matrix; 1990 Oct; 10(5):285-91. PubMed ID: 1964712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cartilage chondrolysis by fibronectin fragments is associated with release of several proteinases: stromelysin plays a major role in chondrolysis.
    Xie DL; Hui F; Meyers R; Homandberg GA
    Arch Biochem Biophys; 1994 Jun; 311(2):205-12. PubMed ID: 8203882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Temporal patterns of stromelysin-1, tissue inhibitor, and proteoglycan fragments in human knee joint fluid after injury to the cruciate ligament or meniscus.
    Lohmander LS; Roos H; Dahlberg L; Hoerrner LA; Lark MW
    J Orthop Res; 1994 Jan; 12(1):21-8. PubMed ID: 8113939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chondrocyte cultures express matrix metalloproteinase mRNA and immunoreactive protein; stromelysin-1 and 72 kDa gelatinase are localized in extracellular matrix vesicles.
    Schmitz JP; Dean DD; Schwartz Z; Cochran DL; Grant GM; Klebe RJ; Nakaya H; Boyan BD
    J Cell Biochem; 1996 Jun; 61(3):375-91. PubMed ID: 8761942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Matrix metalloproteinase (stromelysin-1) increases the albumin permeability of isolated rat glomeruli.
    Sharma R; Suzuki K; Nagase H; Savin VJ
    J Lab Clin Med; 1996 Sep; 128(3):297-303. PubMed ID: 8783637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor necrosis factor bifunctionally regulates matrix metalloproteinases and tissue inhibitor of metalloproteinases (TIMP) production by human fibroblasts.
    Ito A; Sato T; Iga T; Mori Y
    FEBS Lett; 1990 Aug; 269(1):93-5. PubMed ID: 2167246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of cell-cell and cell-matrix interactions on the response of fibroblasts to epidermal growth factor in vitro. Expression of collagen type I, collagenase, stromelysin and tissue inhibitor of metalloproteinases.
    Colige AC; Lambert CA; Nusgens BV; Lapière CM
    Biochem J; 1992 Jul; 285 ( Pt 1)(Pt 1):215-21. PubMed ID: 1637302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Excess of metalloproteases over tissue inhibitor of metalloprotease may contribute to cartilage degradation in osteoarthritis and rheumatoid arthritis.
    Martel-Pelletier J; McCollum R; Fujimoto N; Obata K; Cloutier JM; Pelletier JP
    Lab Invest; 1994 Jun; 70(6):807-15. PubMed ID: 8015285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Purification of the neutral proteoglycan-degrading metalloproteinase from human articular cartilage tissue and its identification as stromelysin matrix metalloproteinase-3.
    Gunja-Smith Z; Nagase H; Woessner JF
    Biochem J; 1989 Feb; 258(1):115-9. PubMed ID: 2930500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of stromelysin activity on proteoglycan degradation of canine articular cartilage explants.
    Todhunter RJ; Yeh LA; Sheldon A; Grisanzio L; Walker SL; Burton-Wurster N; Lust G
    Am J Vet Res; 1995 Sep; 56(9):1241-7. PubMed ID: 7486406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The chondroprotective drugs, Arteparon and sodium pentosan polysulphate, increase collagenase activity and inhibit stromelysin activity in vitro.
    Nethery A; Giles I; Jenkins K; Jackson C; Brooks P; Burkhardt D; Ghosh P; Whitelock J; O'Grady RL; Welgus HG
    Biochem Pharmacol; 1992 Oct; 44(8):1549-53. PubMed ID: 1384503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leukemic cells (HL-60) produce a novel extracellular matrix-degrading proteinase that is not inhibited by tissue inhibitors of matrix metalloproteinases (TIMPs).
    Dittmann KH; Lottspeich F; Ries C; Petrides PE
    Exp Hematol; 1995 Feb; 23(2):155-60. PubMed ID: 7828672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.